The China central lab market size accounted for USD 452.07 million in 2025 and is predicted to increase from USD 506.89 million in 2026 to approximately USD 1287.16 million by 2035, expanding at a CAGR of 10.91% from 2026 to 2035. Central labs use automation, outsourcing, and AI-driven technology to speed up drug advancement, lower expenses, and enhance clinical trial precision, which drives the growth of the market.
Central laboratories analyse blood, tissue, urine, and different specimens via biochemical assays. The central lab helps the work of healthcare trials through processing the laboratory samples drawn from research participants. A central lab supports aid data consistency by lowering the variability often related to questionable data. A central laboratory is a central location where all the samples obtained from a trial’s investigator sites are processed using consistent technology and tools for specialty and massive-volume safety testing. A central lab’s pre-analytical solutions encompass all required preparations ahead of clinical trial lab testing. The central lab has a wide range of abilities in anatomic pathology supported by immunohistochemistry (IHC), chromogenic in situ hybridization, and molecular research. Around 47.3% of middle-aged and older adult patients had at least one health check-up.
Recent advancements in digital biobanking are transforming the management and application of biological resources, creating the opportunity for ground-breaking healthcare and other discoveries. Digital biobanking achieves, supplies, and analyses biological samples and information using digital systems and well-developed technologies. Technological progress has transformed biobanking from traditional to modern forms, with an increasing widespread digital adoption. These biobanks, automated stations manage biospecimen transport, aliquoting, and storage. This technology allows digital tracking of storage conditions and routing.
By services, the biomarker testing services segment contributed the largest China central lab market share of 28% in 2025, as this testing leads to treatments with fewer adverse effects, lengthier survival, and enables patients to avoid treatments that may be ineffective or unnecessary. Comprehensive biomarker testing is often done with a panel test, which assesses multiple biomarkers in one test, as compared to single-marker testing that assesses one marker per test.
By therapeutic area, the oncology segment contributed the largest China central lab market share of 34%, as central labs speed up oncology trials through offering investigator sites with streamlined strategies for the collection and processing of lab samples. This improves the reliability of output and reduces the time between sample collection and data analysis, accelerating the inclusive trial timeline.
By end user, the pharmaceutical companies segment held a significant share of 39% in the market, as central labs have the advanced infrastructure to handle massive volumes of clinical trial samples effectively, which is beneficial for large-scale clinical trials, including multiple sites. Their centralized structure enables streamlined sample management, ensuring samples are processed and analyzed rapidly, lowering turnaround times and allowing faster decision-making.
By technology, the molecular diagnostics segment contributed the largest China central lab market share of 33%, as molecular diagnostics generally provides marvellous time savings in the laboratory, enabling physicians earlier access to information and thus better treatment for patients. Molecular diagnostics has many benefits over traditional diagnostic technology, involving rapid turnaround time, increased accuracy, improved sensitivity, and the capability to detect diseases at an early phase.
Meanwhile, IQVIA Laboratories, this company operates a modern, CAP-accredited central lab in Beijing equipped with full-service clinical trial services. WuXi AppTec provides comprehensive central lab testing platforms handling small and large molecules. KingMylab provides a one-stop lab solution for the entire drug development cycle. Teddy Clinical Research Laboratory, an integrated lab platform associated with Tigermed, specifying in bioanalysis, biomarkers, and NMPA submission support.
By Service Type
By Therapeutic Area
By End User
By Test Type
By Phase of Clinical Trial
By Technology
By Sample Type
